Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | Amyloidosis Sessions: Highlights from ISA 2022

Morie Gertz and Vaishali Sanchorawala • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases Antibodies Daratumumab

Welcome to The Amyloidosis Sessions brought to you by the Video Journal of Hematological Oncology (VJHemOnc). This exclusive session a discussion from the 18th Meeting of the International Society of Amyloidosis (ISA) with leading experts Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, who share their highlights in amyloidosis from the meeting.

More from Morie Gertz

Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis
1:36
Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis
Morie Gertz • 21 Nov 2022
The role of allogeneic transplantation in patients with multiple myeloma
1:33
The role of allogeneic transplantation in patients with multiple myeloma
Morie Gertz • 21 Nov 2022
The importance of identifying AH amyloidosis in patients with normal free light chain levels
1:34
The importance of identifying AH amyloidosis in patients with normal free light chain levels
Morie Gertz • 21 Nov 2022
MRD as a prognostic tool but not for clinical decision-making in multiple myeloma
1:37
MRD as a prognostic tool but not for clinical decision-making in multiple myeloma
Morie Gertz • 21 Nov 2022

More from Vaishali Sanchorawala

Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis
2:17
Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis
Vaishali Sanchorawala • 8 Dec 2025
Cardiac safety of two Dara-VCd dosing schedules in newly diagnosed AL amyloidosis: AQUARIUS trial
5:43
Cardiac safety of two Dara-VCd dosing schedules in newly diagnosed AL amyloidosis: AQUARIUS trial
Vaishali Sanchorawala • 8 Dec 2025
Key agents of interest in the AL amyloidosis space with trial updates presented at ASH 2025
1:03
Key agents of interest in the AL amyloidosis space with trial updates presented at ASH 2025
Vaishali Sanchorawala • 8 Dec 2025
Amyloidosis Sessions: Highlights from ASH 2024
Amyloidosis Sessions: Highlights from ASH 2024
Ashutosh Wechalekar et al. • 8 Dec 2024

Related Videos

Promising therapies and approaches for systemic mastocytosis
0:58
Promising therapies and approaches for systemic mastocytosis
Deepti Radia • 12 Jun 2026
The hottest updates in MPNs from EHA 2026
4:52
The hottest updates in MPNs from EHA 2026
Prithviraj Bose • 11 Jun 2026
Final analysis of the APOLLO trial: ATRA-ATO versus AIDA in high-risk acute promyelocytic leukemia
4:17
Final analysis of the APOLLO trial: ATRA-ATO versus AIDA in high-risk acute promyelocytic leukemia
Maria Teresa Voso • 12 Jun 2026
Bezuclastinib in advanced systemic mastocytosis: the APEX trial
2:34
Bezuclastinib in advanced systemic mastocytosis: the APEX trial
Daniel DeAngelo • 11 Jun 2026
The content of VJHemOnc is intended for healthcare professionals